Stifel Nicolaus Cuts OptimizeRx (NASDAQ:OPRX) Price Target to $8.00

OptimizeRx (NASDAQ:OPRX) had its price objective dropped by equities researchers at Stifel Nicolaus from $13.00 to $8.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ target price indicates a potential upside of 83.07% from the stock’s previous close.

A number of other research analysts also recently issued reports on the company. B. Riley started coverage on OptimizeRx in a research note on Thursday, July 25th. They issued a “buy” rating and a $18.50 price objective for the company. Royal Bank of Canada decreased their price objective on shares of OptimizeRx from $17.00 to $14.00 and set an “outperform” rating for the company in a report on Friday, August 16th. JMP Securities dropped their target price on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating on the stock in a research note on Thursday. Finally, Barclays decreased their price target on shares of OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a research note on Thursday. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, OptimizeRx presently has an average rating of “Moderate Buy” and an average price target of $10.70.

OptimizeRx Stock Down 28.9 %

Shares of OPRX stock traded down $1.78 during trading hours on Thursday, reaching $4.37. The company had a trading volume of 153,767 shares, compared to its average volume of 132,296. The company has a market cap of $80.07 million, a price-to-earnings ratio of -4.35 and a beta of 1.32. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.07 and a quick ratio of 3.07. OptimizeRx has a 12 month low of $4.27 and a 12 month high of $16.65. The business has a fifty day simple moving average of $6.75 and a 200-day simple moving average of $9.07.

Institutional Trading of OptimizeRx

Several large investors have recently added to or reduced their stakes in the stock. First Light Asset Management LLC grew its holdings in shares of OptimizeRx by 5.1% during the 2nd quarter. First Light Asset Management LLC now owns 1,826,961 shares of the company’s stock worth $18,270,000 after acquiring an additional 89,377 shares during the period. Vanguard Group Inc. boosted its holdings in shares of OptimizeRx by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 1,027,293 shares of the company’s stock valued at $12,482,000 after buying an additional 6,291 shares in the last quarter. AWM Investment Company Inc. increased its stake in shares of OptimizeRx by 4.0% in the 1st quarter. AWM Investment Company Inc. now owns 853,042 shares of the company’s stock worth $10,364,000 after acquiring an additional 33,000 shares in the last quarter. Blair William & Co. IL increased its stake in shares of OptimizeRx by 5.6% in the 1st quarter. Blair William & Co. IL now owns 782,573 shares of the company’s stock worth $9,508,000 after acquiring an additional 41,469 shares in the last quarter. Finally, Rice Hall James & Associates LLC lifted its position in OptimizeRx by 24.0% during the 3rd quarter. Rice Hall James & Associates LLC now owns 615,441 shares of the company’s stock valued at $4,751,000 after acquiring an additional 119,306 shares during the period. Institutional investors own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.